Nov 17 (Reuters) - ProMetic Life Sciences Inc PLI.TO
* ProMetic's PBI-4050 demonstrates early evidence of efficacy in its idiopathic pulmonary fibrosis ("IPF") phase 2 clinical trial Source text for Eikon: ID:nPnbmnZhNa Further company coverage: PLI.TO